Your Trusted Brand for Over 35 Years

Kidney Health References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. NIDDK. Anemia in Kidney Disease and Dialysis 2001 Apr. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (
  2. NCHS. Current Estimates from the National Health Interview Survey, 1996. 1999 Oct, Series 10(200). Atlanta, GA: National Center for Health Statistics/Centers for Disease Control and Prevention/U.S. Department of Health and Human Services.
  3. Grantham, J.J., Nair, V., Winklhofer, F. Cystic disease of the kidney. In Brenner & Rector's The Kidney, Volume 2, Sixth Edition 2000, pp. 1699-1730. Philadelphia, PA: W.B. Saunders.
  4. USRDS. USRDS 2001 Annual Data Report 2001 Nov 21. U.S. Renal Data System. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (
  5. LaPorte, J. et al. Kidney stones. How to identify the cause and prevent recurrence. Postgrad. Med. 1990 Apr; 87(5): 219-23, 226.
  6. NIDDK. Kidney and Urologic Diseases Statistics for the United States 2001b Dec. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (
  7. NIDDK. What Are Kidney Stones? 1998. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (
  8. University of New Hampshire (UNH) Health Services. The Body Art Project: The Urinary System. Available at: Last updated 2012. Accessed October 1, 2012.
  9. NORD. Renal Disease Overview 2002. Universal City, CA: National Organization for Renal Disease (
  10. Ettinger, B. et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J. Urol. 1997 Dec; 158(6): 2069-73.
  11. Takei, K., Ito, H., Masai, M., Kotake, T. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. Urol. Int. 1998; 61(3): 192-5.
  12. Williams, C.P., Child, D.F., Hudson, P.R., Davies, G.K., Davies, M.G., John, R., Anandaram, P.S., De Bolla, A.R. Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study. J. Clin. Pathol. 2001 Jan; 54(1): 54-62.
  13. Ohgitani, S., Fujita, T. Calcium decreases urinary oxalate. Nippon Ronen Igakkai Zasshi 2000 Oct; 37(10): 805-10 (in Japanese).
  14. Rodgers, A.L. et al. Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. Urol. Int. 1997; 58(2): 93-9.
  15. Rodgers, A.L. et al. Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. Urol. Int. 1997;58(2): 93-9.
  16. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). What Are Kidney Stones? 1998. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse/ National Institute of Diabetes & Digestive & Kidney Diseases.
  17. Merta, M., Stekrova, J., Zidovska, J., Vorsilkova, M., Walterova, J., Kapras, J., Alanova, M., Raskova, D., Gaillyova, R., Archmanova, E., Rysava, R. DNA diagnosis and clinical manifestations of autosomal dominant polycystic kidney disease. Folia Biol. 1997; 43(5): 201-4.
  18. Sessa, A., Ghiggeri, G.M., Turco A.E. Autosomal dominant polycystic kidney disease: clinical and genetic aspects. J. Nephrol. 1997 Nov-Dec; 10(6): 295-310.
  19. Glanze, W.D. The Mosby Medical Encyclopedia, Revised Edition 1996. St. Louis, MO: C.V. Mosby.
  20. Bacallao, R.L., Carone, F.A. Recent advances in the understanding of polycystic kidney disease. Curr. Opin. Nephrol. Hypertens. 1997 Jul; 6(4): 377-83.
  21. Yuan, C.F., Lin, C.Y., Chen, T.W., Yang, M.L., Ng, H.T. Linkage analysis of families with autosomal dominant polycystic kidney disease by KG8-CA marker. Zhonghua Yi Xue Za Zhi 1997 Sep; 60(3): 125-9.
  22. Grantham, J.J. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int. Suppl. 1997 Dec; 63: S93-S97.
  23. Brkljacic, B. et al. Renal vascular resistance in autosomal dominant polycystic kidney disease. Evaluation with color Doppler ultrasound. Acta Radiol. 1997 Sep; 38(5): 840-6.
  24. Chapman, A.B., Johnson, A.M., Rainguet, S., Hossack, K., Gabow, P., Schrier, R.W. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1997 Aug; 8(8): 1292-7.
  25. Miller-Hjelle, M.A. et al. Polycystic kidney disease: an unrecognized emerging infectious disease? Emerg. Infect. Dis. 1997 Apr-Jun; 3(2): 113-27.
  26. Miller-Hjelle, M.A. et al. Polycystic kidney disease: an unrecognized emerging infectious disease? Emerg. Infect. Dis. 1997 Apr-Jun;3(2): 113-27.
  27. Fored, C.M., Ejerblad, E., Lindblad, P., Fryzek, J.P., Dickman, P.W., Signorello, L.B., Lipworth, L., Elinder, C.G., Blot, W.J., McLaughlin, J.K., Zack, M.M., Nyren, O. Acetaminophen, aspirin, and chronic renal failure. N. Engl. J. Med. 2001 Dec 20; 345(25): 1801-8; comment, N. Engl. J. Med. 2001 Dec 20; 345(25): 1844-6.
  28. NIDDK. Kidney Diseases Dictionary Index 1999. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (
  29. Welch, G.N., Loscalzo, J. Homocysteine and atherothrombosis. N. Engl. J. Med. 1998 Apr 9; 338(15): 1042-50.
  30. Dierkes, J. et al. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin. Nephrol. 1999 Feb; 51(2): 108-15.
  31. Marangon, K., O'Byrne, D., Devaraj, S., Jialal, I. Validation of an immunoassay for measurement of plasma total homocysteine. Am. J. Clin. Pathol. 1999 Dec; 112(6): 757-62.
  32. Levin, A., Stevens, L., McCullough, P.A. Cardiovascular disease and the kidney: tracking a killer in chronic kidney disease. Postgrad. Med. 2002; 111(4): 53-60.
  33. Joosten, E., Lesaffre, E., Riezler, R., Ghekiere, V., Dereymaeker, L., Pelemans, W., Dejaeger, E. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J. Gerontol. A Biol. Sci. Med. Sci. 1997 Mar; 52(2): M76-M79.
  34. McCaddon, A., Davies, G., Hudson, P., Tandy, S., Cattell, H. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 1998 Apr; 13(4): 235-9.
  35. Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., D'Agostino, R.B., Wilson, P.W., Wolf, P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002 Feb 14; 346(7): 476-83.
  36. McCully, KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 1969 Jul; 56(1): 111-28.
  37. Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B., Graham, I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 1991 Apr 25; 324(17): 1149-55.
  38. Ueland, P.M., Ulvik, R.J., Refsum, H. Routine determination of homocysteine in plasma. A new and improved possibility for risk evaluation and diagnosis of common diseases. Tidsskr. Nor. Laegenforen. 1992 Sep 30; 112(23): 2977-80 (in Norwegian).
  39. Stampfer, M.J., Malinow, M.R., Willett, W.C., Newcomer, L.M., Upson, B., Ullmann, D., Tishler, P.V., Hennekens, C.H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. JAMA 1992 Aug 19; 268(7): 877-81.
  40. Stampfer, M.J., Malinow, M.R. Can lowering homocysteine levels reduce cardiovascular risk? N. Engl. J. Med. 1995 Feb 2; 332(5): 328-9.
  41. Selhub, J., Jacques, P.F., Bostom, A.G., D'Agostino, R.B., Wilson, P.W., Belanger, A.J., O'Leary, D.H., Wolf, P.A., Schaefer, E.J., Rosenberg, I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 1995 Feb 2; 332(5): 286-91.
  42. Chauveau P, Chadefaux B, Coudé M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl. 1993;41:S72-7.
  43. van Guldener, C., Stehouwer, CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin. Thromb. Hemost. 2000; 26(3): 281?9.
  44. Hoffer, L.J., Robitaille, L., Elian, K.M., Bank, I., Hongsprabhas, P., Mamer, O.A. Plasma reduced homocysteine concentrations are increased in end-stage renal disease. Kidney Int. 2001 Jan; 59(1): 372-7.
  45. Suliman, M.E., Lindholm, B., Barany, P., Bergstrom, J. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin. Chem. Lab. Med. 2001 Aug; 39(8): 734-8.
  46. Friedman, A.N., Bostom, A.G., Selhub, J., Levey, A.S., Rosenberg, I.H. The kidney and homocysteine metabolism. J. Am. Soc. Nephrol. 2001 Oct; 12(10): 2181-9.
  47. Herrmann, W., Schorr, H., Geisel, J., Riegel, W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin. Chem. Lab. Med. 2001 Aug; 39(8): 739-46.
  48. Bostom, A.G., Shemin, D., Lapane, K.L., Hume, A.L., Yoburn, D., Nadeau, M.R., Bendich, A., Selhub, J., Rosenberg, I.H. High-dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996 Jan; 49(1): 147-52.
  49. Chauveau, P., Chadefaux, B., Coude, M., Aupetit, J., Kamoun, P., Jungers, P. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner. Electrolyte Metab. 1996; 22(1-3): 106-9.
  50. Robinson, K., Gupta, A., Dennis, V., Arheart, K., Chaudhary, D., Green, R., Vigo, P., Mayer, E.L., Selhub, J., Kutner, M., Jacobsen, D.W. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996 Dec 1; 94(11): 2743-8.
  51. Sadava, D., Luo, P.W., Casper, J. Induction of renal damage in rats by a diet deficient in antioxidants. Nutr. Res. 1996; 16(9): 1607-12.
  52. Tucker, K.L., Mahnken, B., Wilson, P.W., Jacques, P., Selhub, J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 1996 Dec 18; 276(23): 1879-85.
  53. Verhoef, P., Stampfer, M.J., Buring, J.E., Gaziano, J.M., Allen, R.H., Stabler, S.P., Reynolds, R.D., Kok, F.J., Hennekens, C.H., Willett, W.C. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am. J. Epidemiol. 1996 May 1; 143(9): 845-59.
  54. Andreotti, F., Burzotta, F., Mazza, A., Manzoli, A., Robinson, K., Maseri, A. Homocysteine and arterial occlusive disease: a concise review. Cardiologia 1999 Apr; 44(4): 341-5.
  55. Li Kam Wa, T.C. Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 1997 Oct; 12(10): 2075-80.
  56. Lingens, N., Freund, M., Seeman, T., Witte, K., Lemmer, B., Scharer, K. Circadian blood pressure changes in untreated children with kidney disease and conserved renal function. Acta Paediatr. 1997 Jul; 86(7): 719-23.
  57. Van der Meide, P.H., Schellekens, H. Cytokines and the immune response. Biotherapy 1996; 8(3-4): 243?9.
  58. Licinio, J., Wong, M.L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 1999 Jul; 4(4): 317?27.
  59. National Kidney Foundation. Millions of Americans May Be at Risk for Kidney Disease: Simple Blood Tests Can Detect Your Risk 2001a Feb 26. New York: National Kidney Foundation (
  60. Navarro, J.F., Mora, C., Rivero, A., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 1999a Mar; 33(3): 458?63.
  61. Boldt, J., Brosch, C., Piper, S.N., Suttner, S. et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit. Care Med. 2001 May; 29(5): 952?8.
  62. Navarro, J.F., Mora, C., Garcia, J. et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand. J. Urol. Nephrol. 1999b Apr; 33(2): 121?5.
  63. USRDS. USRDS 2012 Annual Data Report. ESRD Payment Policy Changes: The New “Bundled” Dialysis Prospective Payment System (PPS) in the United States. Available at: Accessed October 9, 2012.
  64. Saionji, K. et al. Homeostasis of antioxidant status in hemodialysis patients. Rinsho Byori 1999 May; 47(5): 461-6 (in Japanese).
  65. Wratten, M.L. et al. Haemolipodialysis. Blood Purif. 1999; 17(2-3): 127-33.
  66. Clermont, G., Lecour, S., Lahet, J., Siohan, P., Vergely, C., Chevet, D., Rifle, G., Rochette, L. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc. Res. 2000 Aug 18; 47(3): 618-23.
  67. Walser, M. et al. Can renal replacement be deferred by a supplemented very low protein diet? J. Am. Soc. Nephrol. 1999 Jan; 10(1): 110-6.
  68. NKF. National Kidney Foundation. Nutritional and Chronic Kidney Disease. 2002. Available at: Accessed October 9, 2012.
  69. National Kidney Foundation. Vitamins and Minerals in Kidney Disease 2001e. New York: National Kidney Foundation.
  70. McGregor, D., Shand, B., Lynn, K. A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron 2000 Jul; 85(3): 215-20.
  71. Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci. 2005 Jun;1043:807-16.
  72. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab. 2007 May;9(3):233-45.
  73. Williams ME. New potential agents in treating diabetic kidney disease: the fourth act. Drugs. 2006;66(18):2287-98.
  74. Alderson NL, Chachich ME, Frizzell N, et al. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia. 2004 Aug;47(8):1385-95.
  75. Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem. 2003a Oct 24;278(43):42012-9.
  76. Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys. 2003b Nov 1;419(1):41-9.
  77. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27(6):605-14.
  78. Nakamura S, Li H, Adijiang A, Pischetsrieder M, Niwa T. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant. 2007 Aug;22(8):2165-74.
  79. Kirsten R, Heintz B, Nelson K, et al. Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency. Eur J Clin Pharmacol. 1988;34(2):133-7.
  80. Hahn, S. et al. Glomerulosclerosis in the remnant kidney rat is modulated by dietary alpha-tocopherol. J. Am. Soc. Nephrol. 1998 Nov; 9(11): 2089-95.
  81. National Kidney Foundation. Phosphorous and Renal Diet 2001c. New York: National Kidney Foundation.
  82. National Kidney Foundation. Potassium and Renal Diet 2001d. New York: National Kidney Foundation.
  83. NIDDK. Anemia in Kidney Disease and Dialysis 2001a Apr. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (
  84. Wanic-Kossowska, M., Bombicki, K., Koziol, L., Czarnecki, R. Levels of L-carnitine in serum of patients with chronic renal failure treated by hemodialysis (HD). Pol. Arch. Med. Wewn. 1998 Apr; 99(4): 314-22.
  85. Sakurauchi, Y. et al. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Am. J. Kidney Dis. 1998 Aug; 32(2): 258-64.
  86. Sloan, R.S., Kastan, B., Rice, S.I., Sallee, C.W., Yuenger, N.J., Smith, B., Ward, R.A., Brier, M.E., Golper, T.A. Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. Am. J. Kidney Dis. 1998 Aug; 32(2): 265-72; comment, Am. J. Kidney Dis. 1999 Aug; 34(2): 400-1.
  87. Kalinowski, M. et al. Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis. Pol. Merkuriusz. Lek. 1999 Feb; 6(32): 76-8.
  88. Gazdikova K, Gvozdjakova A, Kucharska J, Spustova V, Braunova Z, Dzurik R. Malondialdehyde and selected antioxidant plasma levels in conservatively treated patients with kidney diseases. Bratisl Lek Listy. 2000;101(9):490-4.
  89. Igarashi T, Nakajima Y, Tanaka M, Otake S. Effect of coenzyme Q10 on experimental hypertension in rats and dogs. J Pharmacol Exp Ther. 1974 Apr;189(1):149-56.
  90. Morotomi Y, Oniki H, Onoyama K, Fukiyama K, Omae T. Effects of coenzyme Q10 on the blood pressure and renal renin content in spontaneously hypertensive rats. Igaku Kenkyu. 1975 Nov;45(5):303-8.
  91. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007Aug;334(2):115-24.
  92. Lippa S, Colacicco L, Bondanini F, et al. Plasma levels of coenzyme Q(10), vitamin E and lipids in uremic patients on conservative therapy and hemodialysis treatment: some possible biochemical and clinical implications. Clin Chim Acta. 2000 Feb 25;292(1-2):81-91.
  93. Dlugosz A, Kuzniar J, Sawicka E, et al. Oxidative stress and coenzyme Q10 supplementation in renal transplant recipients. Int Urol Nephrol. 2004;36(2):253-8.
  94. Farswan M, Rathod SP, Upaganlawar AB, Semwal A. Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. Indian J Exp Biol. 2005 Oct 2005;43(10):845-8.
  95. Upaganlawar A, Farswan M, Rathod S, Balaraman R. Modification of biochemical parameters of gentamicin nephrotoxicity by coenzyme Q10 and green tea in rats. Indian J Exp Biol. 2006 May;44(5):416-8.
  96. Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther. 2007 Jun;6(2):104-9.
  97. Wojcikowski K, Stevenson L, Leach D, Wohlmuth H, Gobe G. Antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using a sequential three-solvent extraction process. J Altern Complement Med. 2007 Jan-Feb;13(1):103-9.
  98. Floersheim GL. Experimental basis for the therapy of Amanita phalloides poisoning. Schweiz Med Wochenschr. 1978 Feb 11;108(6):185-97.
  99. Vogel G, Braatz R, Mengs U. On the nephrotoxicity of alpha-amanitin and the antagonistic effects of silymarin in rats. Agents Actions. 1979 Jun;9(2):221-6.
  100. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M, European Society of Clinical Pharmacy Special Interest Group on Cancer C. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008 May;61(6):903-9.
  101. Machado V, Cabral A, Monteiro P, Goncalves L, Providencia LA. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol. 2008 Oct;27(10):1277-96.
  102. Bokemeyer C, Fels LM, Dunn T, et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer. 1996 Dec;74(12):2036-41.
  103. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant. 1996 Jan;11(1):55-62.
  104. Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med. 2005 Sep;2(3):383-6.
  105. El-Shitany NA, El-Haggar S, El-desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008 Jul;46(7):2422-8.
  106. Venkatesan, N., Punithavathi, D., Arumugam, V. Curcumin prevents adriamycin nephrotoxicity in rats. Br. J. Pharmacol. 2000 Jan; 129(2): 231-4.
  107. Suresh Babu, P., Srinivasan, K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol. Cell. Biochem. 1998 Apr; 181(1-2): 87-96.
  108. Naidu, M.U., Shifow, A.A., Kumar, K.V., Ratnaker, K.S. Ginkgo biloba extract ameliorates gentamicin-induced nephrotoxicity in rats. Phytomedicine 2000 Jun; 7(3): 191-7.
  109. Umegaki, K., Shinozuka, K., Watarai, K., Takenaka, H., Yoshimura, M., Daohua, P., Esashi, T. Gingo biloba extract attenuates the development of hypertension in dioxycorticosterone acetate-salt hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2000 Apr; 27(4): 277-82.
  110. Fukaya, H., Kanno, H. Experimental studies of the protective effect of ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats. Nippon Jibinkoka Gakkai Kaiho 1999 Jul; 102(7): 907-17 (in Japanese).
  111. Caimi G, Carollo C, Lo Presti R. Chronic renal failure: oxidative stress, endothelial dysfunction and wine. Clin Nephrol. 2004 Nov;62(5):331-5.
  112. Bertelli AA, Migliori M, Panichi V, et al. Resveratrol, a component of wine and grapes, in the prevention of kidney disease. Ann N Y Acad Sci. 2002 May;957:230-8.
  113. Giovannini L, Migliori M, Longoni BM, et al. Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc Pharmacol. 2001 Mar;37(3):262-70.
  114. Saito M, Satoh S, Kojima N, et al. Effects of a phenolic compound, resveratrol, on the renal function and costimulatory adhesion molecule CD86 expression in rat kidneys with ischemia/reperfusion injury. Arch Histol Cytol. 2005;68(1):41-9.
  115. Chander V, Chopra K. Role of nitric oxide in resveratrol-induced renal protective effects of ischemic preconditioning. J Vasc Surg. 2005a Dec;42(6):1198-205.
  116. Chander V, Tirkey N, Chopra K. Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism. Toxicology. 2005b May 15;210(1):55-64.
  117. Chander V, Chopra K. Protective effect of nitric oxide pathway in resveratrol renal ischemia-reperfusion injury in rats. Arch Med Res. Jan 2006a;37(1):19-26.
  118. Chander V, Chopra K. Protective effect of resveratrol, a polyphenolic phytoalexin on glycerol-induced acute renal failure in rat kidney. Ren Fail. 2006b;28(2):161-9.
  119. Kolgazi M, Sener G, Cetinel S, Gedik N, Alican I. Resveratrol reduces renal and lung injury caused by sepsis in rats. J Surg Res. 2006 Aug;134(2):315-21.
  120. Silan C, Uzun O, Comunoglu NU, Gokcen S, Bedirhan S, Cengiz M. Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol. Biol Pharm Bull. 2007 Jan;30(1):79-83.
  121. Do Amaral CL, Francescato HD, Coimbra TM, et al. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol. 2008 Jun;82(6):363-70.
  122. Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology. 2006;76(2):69-75.
  123. Amudha G, Josephine A, Varalakshmi P. Role of lipoic acid in reducing the oxidative stress induced by cyclosporine A. Clin Chim Acta. Oct 2006;372(1-2):134-9.
  124. Takaoka M, Ohkita M, Kobayashi Y, Yuba M, Matsumura Y. Protective effect of alpha-lipoic acid against ischaemic acute renal failure in rats. Clin Exp Pharmacol Physiol. 2002 Mar;29(3):189-94.
  125. Sehirli O, Sener E, Cetinel S, Yuksel M, Gedik N, Sener G. Alpha-lipoic acid protects against renal ischaemia-reperfusion injury in rats. Clin Exp Pharmacol Physiol. 2008 Mar ;35(3):249-55.
  126. Malarkodi KP, Balachandar AV, Varalakshmi P. Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney. Mol Cell Biochem. 2003a May;247(1-2):9-13.
  127. Malarkodi KP, Balachandar AV, Varlakshmi P. The influence of lipoic acid on adriamycin-induced hyperlipidemic nephrotoxicity in rats. Mol Cell Biochem. 2003b May;247(1-2):139-45.
  128. Amudha G, Josephine A, Mythili Y, Sundarapandiyan R, Varalakshmi P. Therapeutic efficacy of DL-alpha-lipoic acid on cyclosporine A induced renal alterations. Eur J Pharmacol. 2007a Oct 1;571(2-3):209-14.
  129. Amudha G, Josephine A, Varalakshmi P. Beneficial effect of DL-alpha-lipoic acid on cyclosporine A induced hyperlipidemic nephropathy in rats. Mol Cell Biochem. 2007b Jul;301(1-2):165-71.
  130. Abdel-Zaher AO, Abdel-Hady RH, Mahmoud MM, Farrag MM. The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage. Toxicology. 2008 Jan 20;243(3):261-70.
  131. Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int. 2005 Apr;67(4):1371-80.
  132. Yokozawa, T., Nakagawa, T., Lee, K.I., Cho, E.J., Terasawa, K., Takeuchi, S. Effects of green tea tannin on cisplatin-induced nephropathy in LLC-PK1 cells and rats. J. Pharm. Pharmacol. 1999 Nov; 51(11): 1325-31.
  133. Wardle, E.N. Antioxidants in the prevention of renal disease. Renal Fail. 1999 Nov; 21(6): 581-91.
  134. Yokozawa, T., Chung, H.Y., He, L.Q., Oura, H. Effectiveness of green tea tannin on rats with chronic renal failure. Biosci. Biotechnol. Biochem. 1996 Jun; 60(6): 1000-5.
  135. Mukoyama, A., Ushijima, H., Nishimura, S., Koike, H., Toda, M., Hara, Y., Shimamura, T. Inhibition of rotavirus and enterovirus infections by tea extracts. Jpn. J. Med. Sci. Biol. 1991 Aug; 44(4): 181-6.
  136. Velasquez, M.T., Bhathena, S.J. Dietary phytoestrogens: a possible role in renal disease protection. Am. J. Kidney Dis. 2001 May; 37(5): 1056-68.
  137. Ranich, T., Bhathena, S.J., Velasquez, M.T. Protective effects of dietary phytoestrogens in chronic renal disease. J. Ren. Nutr. 2001 Oct; 11(4): 183-93.
  138. Tomobe, K., Philbrick, D.J., Ogborn, M.R., Takahashi, H., Holub, B.J. Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. Am. J. Kidney Dis. 1998 Jan; 31(1): 55-61.
  139. Aukema, H.M., Housini, I., Rawling, J.M. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J. Am. Soc. Nephrol. 1999 Feb; 10(2): 300-8.
  140. Ogborn, M.R., Nitschmann, E., Weiler, H.A., Bankovic-Calic, N. Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int. 2000 Jan; 57(1): 159-66.
  141. Trachtman, H., Sturman, J.A. Taurine: a therapeutic agent in experimental kidney disease. Amino Acids 1996; 11(1): 1-13.
  142. Franconi, F., Bennardini, F., Mattana, A. et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am. J. Clin. Nutr. 1995; 61: 1115-9.
  143. Chambers, S.T. Betaines: their significance for bacteria and the renal tract. Clin. Sci. 1995; 88(1): 25-7.
  144. Wilcken, D.E., Wilcken, B., Dudman, N.P.B., Tyrrell, P.A. Homocystinuria--the effects of betaine in the treatment of patients not responsive to pyridoxine. N. Engl. J. Med. 1983; 309: 448-53.
  145. Wendel, U., Bremer, H.J. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Eur. J. Pediatr. 1984; 142: 147-50.
  146. Gahl, W.A., Bernardini, I., Chen, S., Kurtz, D., Horvath, K. The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria. J. Inherit. Metab. Dis. 1988; 11: 291-8.
  147. Barak, A.J., Beckenhauer, H.C., Tuma, D.J. Betaine, ethanol, and the liver: a review. Alcohol 1996; 13: 395-8.
  148. Selhub, J. Homocysteine metabolism. Annu. Rev. Nutr. 1999; 19: 217-46.
  149. van Guldener, C., Janssen, M.J., de Meer, K. et al. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. J. Intern. Med. 1999; 245: 175-83.